Masimo Corp. today announced that it has entered into an agreement to be acquired by Danaher Corp. for $9.9 billion, or $180 per share.
The Irvine-based medical device maker would become a standalone business unit and brand within Washington-based Danaher’s diagnostic segment upon the deal closing, according to Masimo.
“We look forward to joining Danaher and continuing our growth and momentum as the global leader in patient monitoring,” Masimo Chief Executive Katie Szyman said in a statement.
Shares in Masimo jumped 34% to $174.85 and a $9.4 billion market cap on news of the acquisition, which is expected to close in the second half of this year (Nasdaq: MASI).
For more information, see the Feb. 23 print edition of the Business Journal. Â
